Yesterday, the SEC continued its undefeated streak in its FY 2016 federal court trials. The SEC announced that on April 29, following a two week trial in the U.S. District Court for the Northern District of Illinois, a jury returned a verdict in favor of the SEC in its case against Stephen D. Ferrone.
The SEC alleged in its complaint that Ferrone, who was CEO of biopharmaceutical company Immunosyn Corp., signed and certified certain public filings that
